CIBC Bancorp USA’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$154K Sell
10,769
-1,964
-15% -$33.8K ﹤0.01% 2043
2026
Q2
$237K Buy
+12,733
New +$185K ﹤0.01% 1683

Other funds holding TRVI

CIBC Bancorp USA's TRVI Position: Q3 2026 in Review

CIBC Bancorp USA reduced its Trevi Therapeutics (TRVI) stake by 15% in Q3 2026, selling an estimated $33.8K and leaving 10,769 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

CIBC Bancorp USA first reported a position in TRVI in Q2 2026 and has held it in 2 quarters since. The position peaked at $237K in Q2 2026. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • CIBC Bancorp USA held 10,769 shares of Trevi Therapeutics worth $154K as of Q3 2026.
  • CIBC Bancorp USA sold 1,964 Trevi Therapeutics shares in Q3 2026, an estimated $33.8K.
  • Trevi Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2043 holding.
  • CIBC Bancorp USA first reported a position in Trevi Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • CIBC Bancorp USA's Trevi Therapeutics position peaked at $237K in Q2 2026.
  • 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.